Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1996;28:397-402

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gohlke, P.
Right arrow Articles by Unger, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gohlke, P.
Right arrow Articles by Unger, T.

(Hypertension. 1996;28:397-402.)
© 1996 American Heart Association, Inc.


Articles

Cardiac and Vascular Effects of Long-term Losartan Treatment in Stroke-Prone Spontaneously Hypertensive Rats

Peter Gohlke; Wolfgang Linz; Bernward A. Scholkens; Gabriele Wiemer; Thomas Unger

the Department of Pharmacology, Christian-Albrechts University Kiel, German Institute for High Blood Pressure Research, Heidelberg (P.G., T.U.), and Hoechst AG Frankfurt (W.L., B.A.S., G.W.) (Germany).

Correspondence to Peter Gohlke, PhD, Department of Pharmacology, Christian Albrechts University Kiel, Hospitalstr. 4, 25601 Kiel, FRG.

In previous studies in stroke-prone spontaneously hypertensive rats (SHRSP), we demonstrated that early-onset, long-term angiotensin-converting enzyme inhibitor treatment improved cardiac function and metabolism and increased aortic cGMP content even at sub-antihypertensive doses. These effects could be prevented by bradykinin type 2 (B2) receptor blockade with icatibant. In the present study, we studied the effects of long-term oral treatment with the angiotensin type 1 (AT1) receptor antagonist losartan (30 mg/kg per day) on functional and biochemical parameters of the heart and on cGMP content in the aorta in SHRSP treated prenatally and subsequently up to the age of 20 weeks. Losartan prevented the development of hypertension and left ventricular hypertrophy. Cardiac function measured ex vivo in isolated perfused hearts was improved, as demonstrated by significant increases in left ventricular pressure (22.4%), differentiated left ventricular pressure (dP/dtmax) (35.1%), and coronary flow (38%). The release of the intracellular enzymes lactate dehydrogenase and creatine kinase and of lactate into the coronary effluent was reduced by 46.4%, 47.2%, and 63.6%, respectively. In myocardial tissue, the concentrations of glycogen and the energy-rich phosphates ATP and creatine phosphate were increased by 43.2%, 33.1%, and 42.4%, respectively, whereas lactate was decreased by 57.0%. The aortic tissue content of cGMP was increased fivefold. Our results demonstrate that chronic blockade of AT1 receptors with losartan improved cardiac function and metabolism and increased aortic cGMP content in SHRSP to an extent similar to that observed previously after long-term angiotensin-converting enzyme inhibitor treatment at a comparably antihypertensive dose. Prevention of hypertension and cardiac hypertrophy as well as stimulation of non-AT1 receptors are discussed to explain the cardiac and vascular actions of losartan.


Key Words: angiotensin-converting enzyme inhibitors • heart • rat, stroke-prone SHR • losartan • receptors, angiotensin • cyclic GMP




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
W. D. Comper, L. M. Hilliard, D. J. Nikolic-Paterson, and L. M. Russo
Disease-dependent mechanisms of albuminuria
Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1589 - F1600.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Forder, D. H. Munzenmaier, and A. S. Greene
Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat
Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1989 - H1996.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. Somoza, M. C. Gonzalez, J. M. Gonzalez, F. Abderrahim, S. M. Arribas, and M. S. Fernandez-Alfonso
Modulatory role of the adventitia on noradrenaline and angiotensin II responses: Role of endothelium and AT2 receptors
Cardiovasc Res, February 1, 2005; 65(2): 478 - 486.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. Kalinowski, T. Matys, E. Chabielska, W. Buczko, and T. Malinski
Angiotensin II AT1 Receptor Antagonists Inhibit Platelet Adhesion and Aggregation by Nitric Oxide Release
Hypertension, October 1, 2002; 40(4): 521 - 527.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
N. Uhlenius, O. Vuolteenaho, and I. Tikkanen
Renin-angiotensin blockade improves renal cGMP production via non-AT2-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 233 - 239.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. Gohlke, S. Weiss, A. Jansen, W. Wienen, J. Stangier, W. Rascher, J. Culman, and T. Unger
AT1 Receptor Antagonist Telmisartan Administered Peripherally Inhibits Central Responses to Angiotensin II in Conscious Rats
J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 62 - 70.
[Abstract] [Full Text]


Home page
J CARDIOVASC PHARMACOL THERHome page
Y.-p. Sun, B.-q. Zhu, A. E. M. Browne, S. Pulukurthy, T. M. Chou, K. Sudhir, S. A. Glantz, P. C. Deedwania, K. Chatterjee, and W. W. Parmley
Comparative Effects of ACE Inhibitors and an Angiotensin Receptor Blocker on Atherosclerosis and Vascular Function
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 175 - 181.
[Abstract] [PDF]


Home page
HypertensionHome page
R. Bravo, B. Somoza, M. Ruiz-Gayo, C. Gonzalez, L. M. Ruilope, and M. S. Fernandez-Alfonso
Differential Effect of Chronic Antihypertensive Treatment on Vascular Smooth Muscle Cell Phenotype in Spontaneously Hypertensive Rats
Hypertension, May 1, 2001; e10(5): .
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Takeda, T. Yoneda, M. Demura, I. Miyamori, and H. Mabuchi
Cardiac Aldosterone Production in Genetically Hypertensive Rats
Hypertension, October 1, 2000; 36(4): 495 - 500.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. Linz, H. Heitsch, B. A. Scholkens, and G. Wiemer
Long-Term Angiotensin II Type 1 Receptor Blockade With Fonsartan Doubles Lifespan of Hypertensive Rats
Hypertension, April 1, 2000; 35(4): 908 - 913.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Makino, M. Sugano, S. Ohtsuka, S. Sawada, and T. Hata
Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats
Cardiovasc Res, December 1, 1999; 44(3): 543 - 548.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. Rizzoni, E. Porteri, A. Piccoli, M. Castellano, G. Bettoni, M. L. Muiesan, G. Pasini, D. Guelfi, M. J. Mulvany, and E. A. Rosei
Effects of Losartan and Enalapril on Small Artery Structure in Hypertensive Rats
Hypertension, August 1, 1998; 32(2): 305 - 310.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. Gohlke, C. Pees, and T. Unger
AT2 Receptor Stimulation Increases Aortic Cyclic GMP in SHRSP by a Kinin-Dependent Mechanism
Hypertension, January 1, 1998; 31(1): 349 - 355.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. Gohlke, I. Kuwer, A. Schnell, K. Amann, G. Mall, and T. Unger
Blockade of Bradykinin B2 Receptors Prevents the Increase in Capillary Density Induced by Chronic Angiotensin-Converting Enzyme Inhibitor Treatment in Stroke-Prone Spontaneously Hypertensive Rats
Hypertension, January 1, 1997; 29(1): 478 - 482.
[Abstract] [Full Text] [PDF]